Ironwood医药 IRWD 深 沪
交易中 03-26 11:25:59 美东时间
3.205
+0.015
+0.47%
华盛通- 最 高3.255
- 今 开3.13
- 成交量 23.83万股
- 最 低 3.13
- 昨 收 3.19
- 总市值 5.23亿
- 52周最高 5.78
- 市盈率 静 21.74
- 换手率 0.15%
- 52周最低 0.5271
- 委 比 49.18%
- 总股本 1.63亿
- 历史最高 18.915
- 量 比 0.20
- 振 幅 3.92%
- 历史最低 0.5271
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility
Small-cap outperformance has narrowed over the last couple of weeks as investor caution increased, with volatility and geopolitical risk weighing on risk appetite and narrowing the performance gap vs....
03-19 01:25
Ironwood Pharmaceuticals director Alexander J. Denner disposes of shares worth USD 20.53 million
Ironwood Pharmaceuticals director Alexander J. Denner disposes of shares worth USD 20.53 million Alexander Denner, a director, reported a disposal of 6.73 million common shares of Ironwood Pharmaceuticals at USD 3.05 per share. Disclaimer: This news brief was created by Public Technologies (PUBT) us
03-18 08:35
Small-Cap healthcare stocks ranked by quant ratings after earnings season
As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factor...
03-13 21:55
BRIEF-Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10
BRIEF-Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10 March 11 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O : IRONWOOD PHARMACEUTICALS INC - SATISFIES LIQUIDITY CONDITIONS IN CREDIT AGREEMENT ON MARCH 10, 2026 - SEC FILING IRONWOOD PHARMACEUTICALS INC - MAT
03-11 19:18
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Larimar Therapeutics (NASDAQ:LRMR) shares moved upwards by 58.4% to $5...
02-26 01:05
Ironwood Pharma Q4 revenue misses analyst expectations due to pricing challenges
Ironwood Pharma Q4 revenue misses analyst expectations due to pricing challenges Overview Biotechnology firm's Q4 revenue missed analyst expectations Q4 adjusted EBITDA missed analyst estimates Company finalized Phase 3 trial design for apraglutide, starting in Q2 2026 Outlook Ironwood expects 2026
02-25 20:18
Ironwood Pharmaceuticals Affirms FY2026 Sales Guidance of $450.000M-$475.000M
Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 million to $450.000 million-$475.000 million.
02-25 20:08
Ironwood Pharmaceuticals Q4 Adj. EPS $(0.01) Misses $0.01 Estimate, Sales $47.709M Miss $50.933M Estimate
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.01 by 200 percent. This is a 200 percent decrease over earnings of $0.01 per share
02-25 20:06
BRIEF-Ironwood Pharmaceuticals Q4 Revenue USD 47.709 Million
BRIEF-Ironwood Pharmaceuticals Q4 Revenue USD 47.709 Million Feb 25 (Reuters) - Ironwood Pharmaceuticals Q4 adjusted net income USD -2.274 million. Q4 adjusted EBITDA USD 10.913 million Q4 basic EPS USD -0.01 Q4 net income USD -2.276 million
02-25 20:05
